Sage Therapeutics shares are trading lower. The company announced topline results from Phase 2 PRECEDENT study of dalzanemdor for the treatment of people with mild cognitive impairment in Parkinson's Disease.
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics announced topline results from its Phase 2 PRECEDENT study of dalzanemdor for treating mild cognitive impairment in Parkinson's Disease, leading to a decrease in its share price.
April 17, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sage Therapeutics shares are trading lower following the announcement of topline results from the Phase 2 PRECEDENT study of dalzanemdor for treating mild cognitive impairment in Parkinson's Disease.
The announcement of the topline results from the Phase 2 PRECEDENT study likely led to investor concerns about the efficacy, potential market size, or regulatory path forward for dalzanemdor, negatively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100